[Hyperfibrinogemia following activator therapy].
D000328:Adult; D001778:Blood Coagulation Disorders / Q000139:chemically induced* / Q000188:drug therapy; D001728:Dicumarol / Q000008:administration & dosage; D004617:Embolism / Q000188:drug therapy; D005032:Ethylestrenol / Q000627:therapeutic use; D005340:Fibrinogen / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D010629:Phenformin / Q000627:therapeutic use; D013300:Streptokinase / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors
D001728:Dicumarol; D005340:Fibrinogen; D006493:Heparin; D005032:Ethylestrenol; D010629:Phenformin; D013300:Streptokinase
Hiperfibrynogenemia po zakończeniu terapii aktywatorowej.